



EBRAINS

# HBP- EBRAINS Bootcamp

Brain-technology ventures

Fundraising

Brussels

May 30<sup>th</sup> -31<sup>st</sup>



Co-funded by  
the European Union

# Objectives of the event

- To discover some of the most relevant brain-technologies developed in HBP - EBRAINS
- To explore together opportunities to invest in different HBP start-up initiatives
- To discuss on entrepreneurship critical issues: barriers to overcome and opportunities to explore



# Practical notes

- Agenda and dynamics of this two-days event: visions, mentoring, pitch sessions, discussions
- Useful material (dossier) is available from the start-ups
- Privacy, confidentiality, disclosure
- Logistics



## AGENDA

DAY 1 (May 30 <sup>th</sup> )	
11:00h – 11:15h	Welcome and introduction to day 1
11:15h – 11:30h	Tour de table
11:30h – 13:00h	Teresa De-Martino EC Scientific Officer Human Brain Project 5 min Pawel Swieboda CEO EBRAINS: EBRAINS challenges 5 min Steven Vermeulen CIO EBRAINS: EBRAINS Innovation challenges 10 min Guillermo Velasco HBP Innovation team: HBP Innovation achievements 10 min Andreas Lymberis - EISMEA - EIC Challenge-based Accelerator: EIC vision 30 min Investors: Funders' vision 30 min
13:00h – 13:30h	Roundtable – Debate
13:30h – 14:30h	Lunch & networking
14:30h – 15:00h	HBP established start-ups: Entrepreneurs' vision
15:00h – 15:45h	Fundraising mentoring
15:45h – 16:45h	Pitch mentoring
16:45h – 17:45h	Pitch practice
17:45h – 19:00h	Wrap-up and transport arrangements
19:00h – 21:00h	Networking dinner

DAY 2 (May 31 <sup>st</sup> )	
09:30h – 10:00h	Introduction to day 2
10:00h – 11:00h	Presentation of investors Asabys Partners SPAIN - Antonio Limatola NLC The European Healthtech Venture Builder NETHERLANDS - Ciara Henessy Angels Santé FRANCE - Caroline Amblard-Sai (on-line) ECS Capital Partners USA - Charles Sidman Machine Ventures USA - Sri Rao, Alberto Calero Broadreach Global USA - Christian Suojanen Other EU - TBC
11:00h – 12:00h	<ul style="list-style-type: none"> <li>• PITCH PROJECT 1 + Investors' inquiries <i>The Virtual Brain (TVB)- Health Data Cloud</i> <i>Petra Ritter</i> 5 + 15 min</li> <li>• PITCH PROJECT 2 + Investors' inquiries <i>Neuromorphic computing mechanism for low-energy edge/IoT applications</i> <i>Michael Hopkins, Jakub Fil</i> 5 + 15 min</li> <li>• PITCH PROJECT 3 + Investors' inquiries <i>Neuroscientific simulation tool, &amp; inspection of AI spiking neural networks</i> <i>Jens Bruchertseifer, Sebastian Spreizer</i> 5 + 15 min</li> </ul>
12:00h – 12:10h	Coffee break
12:10h – 13:30h	<ul style="list-style-type: none"> <li>• PITCH PROJECT 4 + Investors' inquiries <i>Medical Informatics Platform</i> <i>Birgit Schaffhauser, Evita Mailli</i> 5 + 15 min</li> <li>• PITCH PROJECT 5 + Investors' inquiries <i>Collaborative Brain Wave Analysis Pipeline</i> <i>Giulia De Bonis, Robin Gutzen</i> 5 + 15 min</li> <li>• PITCH PROJECT 6 + Investors' inquiries <i>Light-sheet microscopy ""Clepia Biotech""</i> <i>Taiana Deodato, Alessandra Franceschini</i> 5 + 15 min</li> <li>• PITCH PROJECT 7 + Investors' inquiries <i>Cutting-edge platform for early identification of new drug candidates</i> <i>Rui Ribeiro</i> 5 + 15 min</li> </ul>
13:30h – 14:30h	Lunch & networking
14:30h – 16:00h	<ul style="list-style-type: none"> <li>• PITCH START-UP 1 + Investors' inquiries <i>"VB Tech" The Virtual Epileptic Patient</i> <i>Jean Marc Ferrier</i> 10 + 20 min</li> <li>• PITCH START-UP 2 + Investors' inquiries <i>"Intrinsic Powers" Tracking &amp; recovering of consciousness in clinical practice.</i> <i>Marcello Massimini</i> 10 + 20 min</li> <li>• PITCH START-UP 3 + Investors' inquiries <i>"Phosphoenix" Prosthesis for blindness</i> <i>Bert Monna, Lisa Kirchberger</i> 10 + 20 min</li> </ul>
16:00h – 16:30h	Final remarks & closing

# Tour de table



Human Brain Project



# HBP Innovation achievements

- How do we support Innovation? The HBP Innovation team
- What is the overall HBP innovation performance? some figures
- Where is European brain-innovation happening?




Human Brain Project

# HBP Innovation team activity (last 18 months)




# Overall innovation & exploitation performance 12 months – evolution (accumulated figures)






# Perceived barriers of innovation (12 months evolution)



- Funding availability is the most important barrier for exploitation
- Funding concerns are clearly increasing during the last phase of the project compared with other types of barriers
- Markets and users are now better identified (market analysis provided should have helped)
- Scaling in the technology readiness levels (TRL) is gradually making groups more confident on the exploitation possibilities of their tools

# Exploitation mode (planned) (%) (12 months evolution)



- HBP researchers' interest in setting up a company (startup or spin-off) is moderate
- In general, the HBP groups seem to prefer delivering consultancy services in the future, rather than signing long agreements with industry
- There is some potential in the Neuroscience educational market

UPM INNOVATION TEAM  
PRESENTS

# WHERE IS EUROPEAN BRAIN-INNOVATION HAPPENING? THE ROLE OF TECH-BASED START-UPS

**AUTHORS:**

GUILLERMO VELASCO, TERIS DURÁN, BLANCA BELTRÁN, GONZALO LEÓN

**CONTRIBUTORS:**

ROMAN KIREEV, BULUT DURMAZ, ALEJANDRO FERNÁNDEZ, EDUARDO SÁNCHEZ



EBRAINS

AN OVERVIEW OF EMERGING BRAIN-TECHNOLOGY  
DEVELOPMENTS AND INDUSTRIAL INITIATIVES

GUILLERMO VELASCO

UNIVERSIDAD POLITÉCNICA DE MADRID

HBP TECHNOLOGY TRANSFER AND INNOVATION TEAM




Human Brain Project

Co-funded by  
the European Union



POLITÉCNICA


CAMPUS  
DE EXCELENCIA  
INTERNACIONAL



# BASIC CHARACTERISATION

(216 BRAIN START-UPS IDENTIFIED, <10 YEARS OLD)

Number of companies identified by country of origin




EBRAINS

# BASIC CHARACTERISATION

(216 BRAIN START-UPS IDENTIFIED)

AREA OF WORK



NEUROPHARMA	22%
ARTIFICIAL INTELLIGENCE	17%
NEUROMONITORING	13%
NEUROIMAGING	9%
NEUROSTIMULATION	9%
NEW DIAGNOSIS METHODS	5%
BIOMARKERS	5%
VIRTUAL REALITY	5%
NEUROROBOTICS	5%
DATA ANALYSIS	4%
SURGERY	4%
GENETICS	2%




EBRAINS

# BASIC CHARACTERISATION

(216 BRAIN START-UPS IDENTIFIED, <10 YEARS OLD)

## MAIN STRENGTHS IDENTIFIED IN (<10 YEARS) EUROPEAN BRAIN TECH START-UPS




EBRAINS

# BASIC CHARACTERISATION

(216 BRAIN START-UPS IDENTIFIED, <10 YEARS OLD)

## MAIN WEAKNESSES IDENTIFIED IN (<10 YEARS) EUROPEAN BRAIN TECH START-UPS



EBRAINS



# Founders' vision

- Opinion on how brain technologies market will evolve, and why to invest on it
- Differences with other industrial/medical areas
- Differences among countries, economies, US, EU



Human Brain Project

# Round table

- In your opinion, what are the major challenges that brain-tech start-ups initiatives must address?
- Why do you find brain-technology and neurocomputing interesting areas to invest?
- What are the most promising areas to focus on?





EBRAINS

Thanks

Contact email: [guillermo.velasco@upm.es](mailto:guillermo.velasco@upm.es)



Co-funded by  
the European Union